Small heat shock proteins in ageing and age-related diseases

Nikolaos Charmpilas, Emmanouil Kyriakakis & Nektarios Tavernarakis
SMALL HEAT SHOCK PROTEINS

Small heat shock proteins in ageing and age-related diseases

Nikolaos Charmpilas1,2 · Emmanouil Kyriakakis1,3 · Nektarios Tavernarakis1,4

Received: 6 November 2016 / Revised: 19 December 2016 / Accepted: 23 December 2016
© Cell Stress Society International 2017

Abstract Small heat shock proteins (sHSPs) are gatekeepers of cellular homeostasis across species, preserving proteome integrity under stressful conditions. Nonetheless, recent evidence suggests that sHSPs are more than molecular chaperones with merely auxiliary role. In contrast, sHSPs have emerged as central lifespan determinants, and their malfunction has been associated with the manifestation of neurological disorders, cardiovascular disease and cancer malignancies. In this review, we focus on the role of sHSPs in ageing and age-associated diseases and highlight the most prominent paradigms, where impairment of sHSP function has been implicated in human pathology.

Keywords Small heat shock proteins · Proteome · Ageing · Neurodegeneration · Cardiovascular disease · Immunity · Cancer

Introduction

Proteins, due to their inherent, unique, biochemical properties and structural diversity, have been selected as the cellular executive macromolecules. The protein reservoir functions amid an environment which is constantly challenged by extrinsic stress factors (such as heat or oxidative stress insults) and intrinsic, potentially harmful agents. For instance, reactive oxygen species (ROS), which are natural by-products of mitochondrial oxidative phosphorylation, can carbonylate polypeptides, damaging them in an irreversible manner (Suzuki et al. 2010). To fulfil the pivotal task of preserving the proteome integrity, evolution has invented elaborate mechanisms to remove polypeptides which have accumulated damage. These include the ubiquitin-proteasome system (UPS) and autophagy which constantly survey cells to eliminate damaged proteins. The activity of the UPS system and autophagy is believed to decline with age and this is accompanied by concomitant trend for aggregation (Labbadia and Morimoto 2014). Considering the importance of the proteome for the cellular functions, it is not surprising that loss of protein homeostasis (proteostasis) is considered as a key hallmark of the ageing process across species (López-Otín et al. 2013).

In parallel to UPS and autophagy, a repertoire of chaperone machines, which are denoted according to their molecular weight (HSP60, HSP70, HSP90, HSP100), functions to refold polypeptides which have acquired an erroneous conformation and prevent the aggregation of misfolded intermediates (Saibil 2013). The genome also encodes for small heat shock proteins (sHSPs), with a molecular mass ranging from 12 to 42 kDa (Haslbeck and Vierling 2015). The members of this protein subfamily are characterized by the presence of a conserved alpha-crystallin domain that is flanked by two amino-acid stretches of lower conservation in the amino and carboxy termini (Franck et al. 2004; Kriehuber et al. 2010).
sHSPs form complexes with abnormal or disordered protein intermediates through both low and high affinity interactions to facilitate their refolding to native conformation or degradation. As such, they are often referred as holdases’ or stabilizers’ in the literature (Treweek et al. 2015). The numerous biological functions of each sHSP may lead to a variety of cell biological consequences with implications on diverse maladies. Here, we review the current knowledge regarding the interplay between sHSP function and ageing, and we particularly emphasize cases where sHSP function or dysfunction is linked with human disease (Table 1).

**sHSPs as ageing modulators: lessons from invertebrate models**

Studies in the nematode *Caenorhabditis elegans* have introduced the intriguing notion that loss of proteostasis is an event which occurs early in adulthood, far before the manifestation of age-related phenotypes (Ben-Zvi et al. 2009; David et al. 2010). The ageing process is characterized by an extensive alteration in the organism’s proteome profile (Walther et al. 2015). The abundance of several sHSP homologues (such as HSP-16.48, HSP-43, HSP-17 and SIP-1) increases in aged nematodes. Moreover, elevated HSP-16.2 and HSP-16.11 expression can be utilized as an efficient predictor of shorter lifespan in an electrotaxis-based assay for assessing lifespan (Manière et al. 2014). Genetic inhibition of various molecular chaperones significantly shortens the organism’s lifespan (Hsu et al. 2003). Intriguingly, *daf-2* mutants for the Insulin/IGF receptor, which live up to three times more than wild type animals, display enormous protein aggregation during ageing. sHSPs are integral components of these aggregates, which may sequester aggregation-sensitive or potentially harmful proteins (Walther et al. 2015). DAF-16, the worm homologue of the FOXO transcription factor and master regulator of ageing downstream of the Insulin/IGF receptor, cooperates with HSF-1 to regulate the expression of several target genes, among which several small heat shock protein genes. Direct regulation of sHSP expression by FOXO has been also observed in *Drosophila melanogaster* in response to oxidative stress (Donovan and Marr 2016). Our research has also elucidated a protective sHSP function in neuron survival upon a heat stroke. In that context HSP-16.1, which localizes to the medial Golgi, fortifies cells against heat stroke-induced neurodegeneration and mediates the beneficial effect of preconditioning in neuron survival (Kourtis et al. 2012). Overall, the activity of sHSPs appears indispensable for longevity and survival under acute stress conditions.

Hsp22 provides a remarkable paradigm of a sHSP family member which lies at the crossroad of mitochondrial metabolism, stress resistance and longevity in *Drosophila melanogaster* (Morrow and Tanguay 2015). Hsp22 localizes in mitochondria and its expression, which is markedly induced as the flies age, can be used as a reliable ageing biomarker (Tower et al. 2014; Yang and Tower 2009). Ubiquitous Hsp22 overexpression is sufficient to prolong lifespan and protect animals against oxidative and heat stress insults, while its heterologous expression in human fibroblasts can delay the onset of senescence in human primary fibroblasts (Morrow et al. 2004; Wadhwa et al. 2010). A recent study also highlights extensive changes in the mitoproteome of Hsp22 overexpressing flies, with several electron transport chain (ETC) and Krebs cycle components markedly affected (Morrow et al. 2016). Interestingly, Hsp22 was shown to associate with ETC complex I components and its overexpression upregulates Hsp70 levels in mitochondria. This implicates Hsp22 in the amplification of a mitoUPR, a salvage response for mitochondrial homeostasis.

**sHSPs in neurological disorders**

α-Crystallin, a complex of αA-crystallin/HSPB4 and αB-crystallin/HSPB5 sHSPs ensure proper light refraction in eye lenses, preventing the detrimental aggregation of itself and other crystallins (β- and γ-). Along ageing, a progressive decline in α-crystallin concentration, which can lead to a concomitant increase in lens stiffness and presbyopia, has been documented (Heyes et al. 2007). Furthermore, several mutations in the α-crystallin domain have been associated with cataract. Prominently, knock-in mice for the R120G missense mutation, which affects its oligomeric state and renders HSPB5 unstable (Treweek et al. 2005), exhibits lens abnormalities, reminiscent of those observed in patients who carry this mutation (Andley et al. 2011). Interestingly, these mice also display elevated levels of p62 close to the nuclear membrane of lens’ epithelial cells, indicating that impaired clearance of insoluble aggregates by autophagy may occur (Wignes et al. 2013). Whether defective autophagy may arise from excessive protein aggregation in the HSPB5R120G over-expressing background, or it rather drives the latter, remains an open question. Intriguingly, a recent report reported the development of pharmacological chaperones’, chemical compounds, which can potentially bind to α-crystallins and reverse their deleterious aggregation (Makley et al. 2015). Their administration can ameliorate protein aggregation defects in both mouse and human tissues.

Some of the most severe neurological disorders, such as Alzheimer’s, Parkinson’s, Huntington and Creutzfeldt Jacobs diseases, are characterized by aberrant formation of insoluble protein inclusions. sHSPs, due to their inherent ability to pre-sequester aggregation-sensitive or potentially harmful proteins, can potentially bind to α-crystallins and inhibit their elongation (Cox et al. 2016; Waudby et al. 2010). A similar protective effect of αB-crystallin was demonstrated in the case of Aβ42 amyloid...
fibrils, which are the hallmarks of Alzheimer’s disease (Shammas et al. 2011). Similarly, upregulation of HSPB8 by administration of colchicine and doxorubicin facilitates the clearance of protein aggregates from neurons. In this case, HSPB8 in cooperation with BAG-3 nucleotide exchange factor facilitates the removal of protein aggregates, probably through autophagy activation (Crippa et al. 2016).

Apart from protein aggregation diseases, sHSPs seem to exert beneficial effects in paradigms where neurons are challenged by harmful insults. For instance, overexpression of αB-crystallin in cultured rat hippocampal neurons protects against heat shock through enhanced dendritic branching (Bartelt-Kirbach et al. 2016). HSPB3, an sHSP which is highly expressed in motor neurons confers protection against lesion-induced neurodegeneration (La Padula et al. 2016). Collectively, sHSPs act protectively in the context of neurodegenerative disease to ameliorate excessive protein aggregation and promote neuron survival.

**sHSPs in motor neuropathies**

Charcot-Marie-Tooth (CMT) belongs to the family of hereditary motor neuropathies (HMN) and is the most widespread inherited neuromuscular disorder affecting approximately 1:2500 individuals. It is a peripheral nervous system disease, since patients with CMT exhibit atrophy in the muscles of the arms and legs, sensory abnormalities, foot deformities and walking difficulties. The disorder has a late-onset, with its symptoms being manifested during adulthood or midlife. Almost a decade ago, two hallmark studies linked specific missense mutations in HSP22/HSPB8 and HSP27/HSPB1 with the manifestation of CMT and HMN (Evgrafov et al. 2004; Irobi et al. 2004). These two chaperones have been reported to physically interact (Sun et al. 2004). Both HSPB8 mutations alter a single amino-acid residue (K141) located in its conserved α-crystallin domain. Intriguingly, mutations in K141 of HSPB8 do not disturb its interaction with HSPB1, but rather enhance it, leading to the formation of cytoplasmic aggregates (Fontaine et al. 2006; Irobi et al. 2004). As for HSP27, numerous mutations predominantly in the α-crystallin domain (R127W, S135F, R136W, T151I) but also in the carboxy-terminal domain (P182L, P182S) have been identified (Evgrafov et al. 2004; Kijima et al. 2005).

<table>
<thead>
<tr>
<th>sHSPs</th>
<th>Organism</th>
<th>Ageing</th>
<th>Mutation</th>
<th>Pathology</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSP-16.48, HSP-43, HSP-17 and SIP-1</td>
<td>C. elegans</td>
<td>Elevated, required for normal lifespan</td>
<td>–</td>
<td>–</td>
<td>(Hsu et al. 2003; Walther et al. 2015)</td>
</tr>
<tr>
<td>HSP22</td>
<td>D. melanogaster</td>
<td>O/E prolongs lifespan</td>
<td>–</td>
<td>–</td>
<td>(Morrow et al. 2016)</td>
</tr>
<tr>
<td>A-Crystallin(HSPB4-HSPB5 complex)</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td>R120G</td>
<td>Presbyopia, Cataracts</td>
<td>(Andley et al. 2011; Heys et al. 2007)</td>
</tr>
<tr>
<td>HSP22/HspB8</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td>K141N</td>
<td>Cardiomyopathy</td>
<td>(Sanbe et al. 2013)</td>
</tr>
<tr>
<td>HSP20/HSPB6</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td>S16A S16D</td>
<td>Cardiac disease</td>
<td>(Martin et al. 2014a; Qian et al. 2009)</td>
</tr>
<tr>
<td>αB-crystallin/HSPB5</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td>R120G</td>
<td>Myopathy and heart failure</td>
<td>(Rajasekaran et al. 2007; Vicart et al. 1998)</td>
</tr>
<tr>
<td>HSPB7</td>
<td>H. sapiens</td>
<td>–</td>
<td>SNP (rs1739843)</td>
<td>Dilated cardiomyopathy</td>
<td>(Stark et al. 2010)</td>
</tr>
<tr>
<td>HSP27/HSPB1</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td></td>
<td>CVD and inflammation</td>
<td>(Batulan et al. 2016; Seibert et al. 2013)</td>
</tr>
<tr>
<td>HSP27/HSPB1</td>
<td>M. musculus, H. sapiens</td>
<td>–</td>
<td></td>
<td>Cancer development</td>
<td>(Acunzo et al. 2012; Arrigo and Gibert 2014)</td>
</tr>
</tbody>
</table>

Small heat shock proteins in ageing and age-related diseases

**Table 1** sHSPs influence lifespan and human pathology. Summary of prominent examples where sHSP function has been associated with lifespan and manifestation of age-associated disease
et al. 2004). The list of variations associated with CMT and HMNs has greatly expanded and nowadays includes mutations which are propagated in both autosomal dominant and recessive manner (Houlden et al. 2008; Ikeda et al. 2009; Kim et al. 2015; Nakho et al. 2013; Stancaneli et al. 2015).

The recent generation of mouse models has provided novel insights concerning the relation between HSP mutations and CMT. Overexpression of either mutant HSPB1 S135F or HSPB1 P182L isoforms in the neuronal system leads to pronounced motor defects and reduced muscle strength, as monitored through behavioural tests (d’Ydewalle et al. 2011; Lee et al. 2015). While there is support for aberrant myelination in the latter study using the HSPB1 S135F model, a decrease in the levels of a-tubulin acetylation seems to be a common denominator of the observed pathology. Tubulin hypoacetylation is associated with impaired transport of mitochondria across axons and in neurites in HSPB1 S135F overexpressing animals, and this defect can be reversed upon administration of histone deacetylase inhibitors (d’Ydewalle et al. 2011). In addition, overexpression of the HSPB1 R136W mutant isoform results in severe axonopathy, defective neurofilament cytoskeleton accumulation of mitochondria along axons (Srivastava et al. 2012). Moreover, the hyperactive HSPB1 mutants (R127W, S135F and R136W) have been reported to display enhanced affinity to tubulin and microtubule stabilization (Almeida-Souza et al. 2011). Thus, the recapitulation of the CMT condition in mice supports the requirement for intact HSPB1 function for preserving cytoskeleton integrity in neurons. Nonetheless, since HSPB1 can have non-conventional and often unanticipated roles in cell physiology, for instance the regulation of abundance and activity of the master regulator GATA-1 during erythroid differentiation (de Thonel et al. 2010), other potential HSPB1 modes of action in neurons should not be a priori excluded.

**sHSPs in cardiovascular disease**

Cardiovascular disease (CVD) is the leading cause of death throughout the developed world. In recent years, huge advancements in the understanding of CVD led to innovative therapeutic interventions and sensational improvement in age-adjusted cardiovascular mortality rates. Undoubtedly, thorough understanding of the underlying mechanisms and identification of novel targets will aid in curtailing CVD prevalence. Emerging evidence implicates sHSPs in the pathogenesis of CVD, and several studies uncovered mutations and single nucleotide polymorphisms in sHSP genes associated with cardiomyopathies (Martin et al. 2014a; Martin et al. 2014b; Raizman et al. 2013; Rajasekaran et al. 2007; Seibert et al. 2013; Stark et al. 2010; Vicart et al. 1998). For instance, even a single point mutation of HSPB8 can cause cardiac disease (Sanbe et al. 2013). Among all sHSP family members, HSPB1 and HSPB6 have traditionally been the main focus of interest of cardiovascular research. A compilation of recent scientific knowledge highlights the cardioprotective properties of these molecules which are predominantly expressed in the cardiovascular system (Edwards et al. 2011; Fan et al. 2005a; Martin et al. 2014a; Weintraub and Rubinstein 2013). The anti-platelet aggregation properties of HSPB6 attracted further attention in the field of cardiovascular research (Kozawa et al. 2002). Under physiological conditions, platelets prevent haemorrhage of the injured vasculature. During atherosclerotic plaque rupture, however, platelet-mediated thrombus may lead to acute coronary syndrome (ACS). HSPB6 specifically binds to platelets, attenuating their aggregation through mechanisms that are incompletely understood. Nevertheless, inducing HSPB6 expression levels in rupture-prone atherosclerotic microenvironments may provide a novel therapeutic approach in ACS. The potential role of HSPB1 in CVD originated from studies of human vascular tissue. HSPB1 secretion decreases in atherosclerotic plaques, compared to healthy tissues, and soluble HSPB1 plasma levels also decline in atherosclerotic patients compared to healthy subjects (Martin-Ventura et al. 2004), whereas overexpression of HSPB1 in atherosclerotic mouse models ameliorates foam cell formation and reduces atherosclerotic plaque area (Rayner et al. 2008). These findings suggest a protective role for sHSPs in atherogenesis, however, the precise mechanisms of action remain obscure, largely due to the diverse nature of each sHSP family member.

**Posttranslational modifications of sHSPs and implications in CVD**

Given the diversity of homo- and hetero-oligomerization as well as their potential for post-translational modification, the functional diversification of sHSPs is further expanded and so is their involvement in CVD progression. sHSPs undergo a variety of post-translational modifications, with phosphorylation being the most prominent (Myrmrikov et al. 2011). HSPB1 was reported to be methylglyoxal modified in endothelial cells exposed to conditions of excessive glucose (Schalkwijk et al. 2006). This methylglyoxal modification modulates the oligomeric population of HSPB1, increases its chaperone activity, reduces its interaction with cytochrome c and modulates its anti-apoptotic activity (Oya-Ito et al. 2006; Padival et al. 2003; Sakamoto et al. 2002; van Heijst et al. 2006). This can potentially contribute to endothelial dysfunction associated with metabolic syndrome and various cardiovascular diseases, such as atherosclerosis. Direct association of methylglyoxal modifications of sHSPs and ageing remains unascertained. An in vitro study suggests that methylglyoxal modification of α-crystallin can enhance its chaperone function and protect the lens against environmental and metabolic stress by preventing nascent polypeptide accumulation associated with ageing (Nagaraj et al. 2003; Nagaraj et al. 2012b). Similarly, HSPB4 acetylation in human lens alters the
chaperone’s function, a process that is essential for impeding the age-associated accumulation of insoluble lens proteins (Nagaraj et al. 2012a). Interestingly, HSPB1 contains an S-thiolation site that is absent in HSPB5 (αB crystallin). During ischemia, reperfusion and oxidative damage, which contributes to the injury sustained by the heart during ischemia and reperfusion, rat cardiac HSPB1 is modified (Eaton et al. 2002a, b). It is proposed that S-thiolation increases the affinity of dissociated HSPB1 multimers for specific target proteins; however, evidence on the functional significance of this post-translational modification remains scarce. Although anticipated, the in vivo role of sHSP phosphorylation is largely ambiguous, and research towards this direction is imperative. Accumulating evidence suggests that it may function as a switch, to enable access to their target clients (Bakthisan et al. 2015). In vitro experiments suggest that phosphorylation influences the oligomeric state of sHSPs and interaction with client proteins and consequently their chaperone-like activity. During precarious and stressful conditions, such as heat shock, serine phosphorylation of several HSPB members such as HSPB1, HSPB4, HSPB5, HSPB6 and HSPB8 may occur. As a consequence, their function is redirected, and a variety of cellular processes are modulated accordingly. For instance, although both HSPB1 and HSPB6 regulate vascular smooth muscle tone, HSPB1 phosphorylation is associated with vasorelaxation, whereas HSPB6 phosphorylation leads to smooth muscle contraction (Dreiza et al. 2010; McLemore et al. 2005), further perplexing the already complicated mode of actions. Furthermore, the phosphorylation status seems to modulate the pro-apoptotic and anti-apoptotic effects of sHSPs; however, further studies are required to elucidate to what extent these modifications are directly related to downstream apoptotic cascades. Further evidence also suggests that it is involved in the regulation of autophagy. Along these lines, it is noteworthy to mention that cell death and autophagy are tightly interrelated with ageing (Pollack and Leeuwenburgh 2001; Rubinszttein et al. 2011). sHSPs may constitute an interchage between autophagy, apoptosis and ageing. Inhibition of HSPB6 phosphorylation at Ser16 results in hearts with larger infarcts, via increased apoptosis and necrosis and reduced autophagy (Qian et al. 2009). In support of these findings, it was demonstrated that miR-320, an miRNA that is upregulated in ischemic hearts, negatively regulates HSPB1 expression. Likewise, HMGB1 induces HSPB1 to attenuate cardiomyocyte apoptosis associated with doxorubicin-induced cardiomyopathy and regulate autophagy and mitochondrial autophagy (mitophagy) (Narumi et al. 2015; Tang et al. 2011). However, involvement of protein phosphorylation in this process remains unknown. Thus, sHSPs phosphorylation status and regulation at the transcriptional and post-transcriptional level may constitute an important modality not only for cardioprotection, but for ageing as well (Fig. 1).

**Extracellular sHSPs in CVD and inflammation**

In recent years, intensive research activity has focused in delineating the role of extracellular sHSPs in the immune system and the modulation of atherosclerosis. Albeit sHSPs lack the N-terminal signal peptide required for extracellular secretion; they have been detected extracellularly. The mechanism involved in sHSPs secretion remains elusive, and several theories have been proposed. Accumulating evidence suggests an exosome-mediated secretion; however, alternative pathways are not yet excluded (Batulan et al. 2016; van Noort et al. 2012). The mode of action of secreted sHSPs is beginning to be addressed, albeit their presence on exosomes, and surmises a possible cell-non-autonomous activity. Exosomes have been detected in various body fluids, including serum, saliva and breast milk and have been associated to cellular senescence and ageing (Xu and Tahara 2013). Hence, they may act not only in an autocrine fashion, but also in a paracrine and endocrine fashion. It is believed that tissue communication may affect longevity in an endocrine fashion, by coupling physiological pathways which regulate ageing. It is suggested that manipulation of cell-non-autonomous signalling pathways may increase health- and life-span by regulating organismal survival during reduced metabolism and under stress conditions. Direct association of secreted sHSPs with cell-non-autonomous effects which impinge on ageing remains elusive. HSPB6 has been characterized as a cardiokine promoting myocardial angiogenesis through activation of VEGFR. Physical interactions of circulating HSPB6 with VEGFR increase capillary density providing a novel protective mechanism against cardiac injury, given that coronary angiogenesis is vital for heart restoration. However, neovessel formation may destabilize atherosclerotic plaques leading to plaque rupture and ACS (Bentzon et al. 2014). Thus, the protective role of HSPB6 in cardiovascular disease needs to be carefully considered and re-evaluated. Lower circulating HSPB1 serum levels were documented in atherosclerotic coronary arteries and were inversely associated with increasing plaque progression and age. Thus, serum release of HSPB1 seems to have an atheroprotective and potentially an anti-ageing role (Batulan et al. 2016; Kardys et al. 2008; Lepedda et al. 2009; Martin-Ventura et al. 2004; Miller et al. 2005; Rayner et al. 2008). In a mouse model of atherosclerosis, exogenous administration of HSPB1 reduced plaque progression, corroborating its atheroprotective properties and further suggesting a potential therapeutic benefit (Seibert et al. 2013). Intriguingly, HSPB1 was first identified as an oestrogen-responsive protein and was subsequently characterized as a sHSP (Ciocca et al. 1983). The association with circulating oestrogen levels further suggests sex-related effects of HSPB1. Indeed, the atheroprotective effects of HSPB1 were more pronounced in female mouse models (Rayner et al. 2008). Since, atherosclerosis is primarily a chronic inflammatory disease, the link between secreted sHSPs and the immune system was soon appraised. Overall, these effects were, at least partially, attributed
to the inflammatory effects of extracellular HSPB1. It has been shown to reduce macrophage infiltration and free serum cholesterol and attenuate foam cell formation. This occurs via down-regulation of scavenger receptor-A expression via NF-$\kappa$B signalling and interaction with toll-like receptors (TLRs) in both cardiovascular and immune cells *inter alia* (Batulan et al. 2016; Jin et al. 2014; Raizman et al. 2013). Secreted sHSPs are now considered potential therapeutic agents to prevent or ameliorate inflammatory processes (van Noort et al. 2012). Interestingly, the association between ageing and immune response mechanisms begins to be appreciated (Nikoletopoulou et al. 2014). During ageing, the immune responses gradually deteriorate, increasing susceptibility to infections and causing low-grade inflammation. This age-associated proinflammatory phenotype, referred to as inflammageing’, is attributed to the imbalance between anti- and pro-inflammatory mechanisms. Deeper understanding of the mechanisms and factors involved in immunosenescence and inflammageing may aid healthy ageing through more efficient pharmacological strategies, where circulating sHSPs could serve as a bona fide therapeutic target.

**sHSPs in cancer**

Although, sHSPs are often overexpressed in cancer cells and are associated with increased tumorigenicity, their precise mode of action remains enigmatic (Acunzo et al. 2012; Arrigo and Gibert 2014). Evading apoptosis is one of the major cancer traits, and since sHSPs have an extremely intricate role in the regulation of apoptosis, these proteins attracted scientific interest to confront carcinogenesis. sHSPs possess mainly anti-apoptotic properties; however, pro-apoptotic features have also been reported (Acunzo et al. 2012; Arrigo and Gibert 2014; Bakthisaran et al. 2015; Guo et al. 2015; Ju et al. 2015; Mymrikov et al. 2011; Zeng et al. 2013). Interestingly, sHSPs interfere with both extrinsic (dependent on death ligands and receptors) and intrinsic (mitochondrial-mediated) apoptotic pathways. For instance, HSPB1 and HSPB5 negatively modulate TNF-$\alpha$ and Fas-induced cell apoptosis; whereas, HSPB2 has been reported to prevent TRAIL and TNF-$\alpha$-induced apoptosis (Mehlen et al. 1996; Oshita et al. 2010; Pinz et al. 2008; Qi et al. 2014). Cytosolic HSPB1 interacts with the mitochondrial outer membrane and directly binds to released cytochrome c to inhibit apoptosome formation (Bruey et al. 2000). Interestingly, HSPB1 expression protects from mitochondrial injury-mediated apoptosis and promotes cell survival by a phosphatidylinositol 3-kinase (PI3-K)-dependent mechanism (Havasi et al. 2008). Subsequent Akt activation inhibits Bax activation, oligomerization and translocation to mitochondria, preventing cytochrome c release. Apparently, it appears that HSPB1 interferes with apoptosis on multiple levels. Apart from preventing cytochrome c release from injured mitochondria, it simultaneously exerts its protective effects upon mitochondrial...
membrane injury by impeding cytochrome c activity upon release. Furthermore, HSPB1 controls the release of second mitochondria-derived activator of caspases (Smac), which promotes apoptosis via caspase activation, and also plays an important role in the p53 pathway, underlining its crucial role in apoptosis and in the regulation of cellular senescence (Bakthisaran et al. 2015; Chauhan et al. 2003; O’Callaghan-Sunol et al. 2007; Xu et al. 2013). Similarly, alpha-crystallins (HSPB4 and HSPB5) and HSPB6 prevent apoptotic cell death through interaction with pro-apoptotic proteins of the Bcl-2 family, such as Bax and Bcl-X(S), intercepting their translocation from cytosol into mitochondria (Fan et al. 2005b; Mao et al. 2004). Additionally, alpha-crystallins preserve mitochondrial integrity and inhibit apoptosis by interacting with cytochrome c and caspase subtypes and by repressing caspase-3 activation (Bakthisaran et al. 2015; Mao et al. 2004; McGreal et al. 2012). Detailed information on the interplay between sHSPs and the extrinsic and intrinsic apoptotic pathways can be found in excellent recent articles (Acunzo et al. 2012; Arrigo and Gibert 2014; Bakthisaran et al. 2015; Mymrikov et al. 2011).

Intriguingly, sHSPs also play essential roles in cancer cell migration, invasion and metastasis, most probably due to their biochemical cytoskeletal related functions (Mounier and Arrigo 2002), and in cancer-related angiogenesis, expanding their pleiotropic effects on cancer development. Metastasis is the leading cause of death for patients suffering from malignancies. The importance of angiogenesis and lymphangiogenesis in cancer development is fundamental, since tumour growth and metastasis primarily depend on the formation of new vessels (Hanahan and Weinberg 2011). HSPB1 increases cancer cell motility, and its overexpression and phosphorylation are associated with increased metastatic and invasive potential of cells both in vivo and in vitro in various cancer types (Gibert et al. 2012; Voll et al. 2014; Yang et al. 2010). Moreover, alpha-crystallins play an important role in cell motility and invasion. Whereas HSPB4 seems to restrain cell migration and to negatively regulate pancreatic carcinogenesis, HSPB5 induces epidermal growth factor (EGF)-independent growth and increases cell migration and invasion (Deng et al. 2010; Moyano et al. 2006). HSPB6 has been recently shown to regulate transforming growth factor-α (TGF-α)-induced migration and invasion of hepatocellular carcinoma cells (Matsushima-Nishiwaki et al. 2016). Interestingly, a phospho-HSPB6 mimetic reduces their invasive potential, illustrating the importance of sHSPs’ post-translational modifications. Moreover, the fact that sHSPs contribute to the metastatic potential and maintenance of cancer stem cells through regulation of epithelial to mesenchymal transition (EMT) is of particular interest. EMT has been shown to play a fundamental role in metastasis. Intriguingly, HSPB1 mediates EMT, metastasis and circulating tumour cells in prostate cancer and breast cancer via modulation of STAT3/Twist signalling and nuclear factor-kappaB (NF-kB) respectively (Shiota et al. 2013; Wei et al. 2011). Endothelial to mesenchymal transition (EndMT) is another parameter known to be important for metastatic extravasation in brain endothelial cells and to promote invasiveness of infected endothelial cells, thus contributing to cancer progression (Gasperini et al. 2012; Krizbai et al. 2015). Endothelial cell function is vital for the maintenance of the vasculature and for neovascularization under pathophysiological conditions. HSPB1 is expressed in tumour vessels and is a key regulator of EndMT in cancer (Choi et al. 2016). Although contradictory to the effects on EMT, the abovementioned effects suggest a key role of HSPB1 in maintaining the vasculature during cancer, by impeding EndMT. The effects of HSPB1 during tumour angiogenesis are also contradictory. Although HSPB1 administration leads to VEGF secretion and angiogenesis, overexpression of HSPB1 leads to aggressive tumour growth in vivo and its downregulation leads to reduced endothelial cell proliferation and decreased secretion of VEGF, suggesting an involvement of HSBP1 in tumour angiogenesis. EC-secreted HSPB1 can also prevent tumour angiogenesis via direct binding with VEGF (Lee et al. 2012; Straume et al. 2012; Thuringer et al. 2013). Other sHSPs promote tumour angiogenesis, mainly through increasing vascular survival. Tumours which develop in HSPB5 mutant mice are significantly less vascularized than wild-type tumours and display increased areas of apoptosis/necrosis (Dimberg et al. 2008).

Overall, sHSPs are mainly considered as oncoproteins due to their anti-apoptotic mode of action; however, more studies are required to unveil their exact role during carcinogenesis. The cytoprotective, anti-apoptotic, pro-angiogenic and pro-metastatic properties of sHSPs, position them as promising targets for anticancer treatment, and a thorough understanding of sHSPs mode of action will allow the development of specific and targeted pharmaceutical interventions. HSPB1 inhibition by OGX-427 is currently in multicentre phase II clinical trials for treatment of metastatic cancer. OGX-427 is a second-generation antisense technology inhibitor that enables targeted downregulation of gene expression at the transcriptional level. It has been shown to potently reduce HSPB1 levels and in synergy with other cancer treatments to inhibit tumour growth, further validating these proteins as potential therapeutic targets for cancer treatment (Baylot et al. 2011; Gleave and Monia 2005; Lamoureux et al. 2014; Lelj-Garolla et al. 2015; Shiota et al. 2013).

Concluding remarks and outlook

Ageing affects many cellular processes and is considered one of the major risk factors for the development and progression of cardiovascular disease, neurodegeneration and cancer. The average lifespan of humans and concomitantly the percentage of elderly people have immensely increased over the past decades. Cardiovascular disease (CVD) will remain the leading cause of mortality within that group and together with
cancer and neuropathies will burden societies with high socioeconomic costs. Till recently, the fields of ageing biology and CVD have remained largely unrelated, although it was known that ageing has a remarkable impact on the heart and arterial system, evidenced as atherosclerosis, hypertension, myocardial infarction and stroke incidents (Lakatta and Levy 2003a, b; North and Sinclair 2012). A plethora of longevity genes initially identified in model organisms, including the nematode Caenorhabditis elegans and the fly Drosophila melanogaster, are currently appraised for their role in CVD (Nair and Ren 2012; North and Sinclair 2012). The link between ageing and cancer has been well documented. Given that lifespan has rapidly increased over the past decades, it is not surprising that worldwide prevalence of cancer will continue to rise and become the prevailing cause of mortality. Understanding fundamental mechanisms that orchestrate the ageing process can lead to significant advancements into both preventative and therapeutic interventions of CVD, neurodegeneration and cancer. Fine-tuning of sHSPs could have beneficial outcomes in various pathologies and in lifespan itself. In CVD and neurodegenerative disorders, tissue-specific up-regulation of sHSPs could prove beneficial; whereas, cofining or completely abrogating several sHSPs could facilitate cancer mitigation. The use of functional inhibitors would be another, perhaps more plausible approach. sHSP function highly depends on posttranslational modifications as well as their ability to form homo- and hetero-oligomeric complexes and interact with various client proteins. In fact, the diverse biochemical functional activities of HSPBs might explain the divergent outcomes. Thus, a deeper understanding of the underlying mechanisms and the precise mode of action of each sHSP is imperative for the design of effective strategies that could be beneficial for increasing life- and health-span.

Acknowledgements We apologize to those colleagues whose work could not be referenced directly owing to space limitations. Work in the authors’ laboratory is funded by grants from the European Research Council (ERC), the European Commission Framework Programmes, and the Greek Ministry of Education. E.K. is supported by Stiftung für Herz- und Kreislaufforschungen.

References

Small heat shock proteins in ageing and age-related diseases


Small heat shock proteins in ageing and age-related diseases


Small heat shock proteins in ageing and age-related diseases


